2779545-15-0
Chemical Structure
(+)-Neoalbaconol
- CAS No.: 2779545-15-0
- Formula:C22H34O3
- Molecular Weight:346.50
InChIKey: MSZVIKVMIYEXQL-YUVXSKOASA-N
SMILES: C[C@@]12[C@H]([C@](O)(CC[C@@]1([H])C(C)(CCC2)C)C)CC3=C(C=C(C=C3O)O)C
Biological Activity: (+)-Neoalbaconol is a selective Akt/PDK1 inhibitor (with an IC50 of 10 μM against hPDK1). (+)-Neoalbaconol selectively inhibits cancer cell proliferation, and induces energy depletion, apoptosis, autophagy and necroptosis in cancer cells. In addition, (+)-Neoalbaconol downregulates cIAP1/2 and TRAFs to activate non-canonical NF-κB and promote TNFα transcription, blocks EGFR-mediated VEGF production and receptor activation, and mediates cell necrosis via the RIPK3-ROS-dependent pathway. (+)-Neoalbaconol can be used in research related to nasopharyngeal carcinoma, melanoma, breast cancer and gastric cancer[1][2][3].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(+)-Neoalbaconol | (+)-Neoalbaconol is a selective Akt/PDK1 inhibitor (with an IC50 of 10 μM against hPDK1). (+)-Neoalbaconol selectively inhibits cancer cell proliferation, and induces energy depletion, apoptosis, autophagy and necroptosis in cancer cells. In addition, (+)-Neoalbaconol downregulates cIAP1/2 and TRAFs to activate non-canonical NF-κB and promote TNFα transcription, blocks EGFR-mediated VEGF production and receptor activation, and mediates cell necrosis via the RIPK3-ROS-dependent pathway. (+)-Neoalbaconol can be used in research related to nasopharyngeal carcinoma, melanoma, breast cancer and gastric cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Deng Q, et al. Neoalbaconol induces energy depletion and multiple cell death in cancer cells by targeting PDK1-PI3-K/Akt signaling pathway. Cell death & disease. 2013 Sep 19;4(9):e804. [Content Brief]
- [2]. Yu X, et al. Neoalbaconol induces cell death through necroptosis by regulating RIPK-dependent autocrine TNFα and ROS production. Oncotarget. 2015 Feb 10;6(4):1995-2008. [Content Brief]
- [3]. Yu X, et al. Neoalbaconol inhibits angiogenesis and tumor growth by suppressing EGFR-mediated VEGF production. Molecular carcinogenesis. 2017 May;56(5):1414-1426. [Content Brief]
